Eagle Biologics, Inc.

Other

Massachusetts Institute of Technology

The General Hospital Corporation

Pandion Operations, Inc.

Xtuit Pharmaceuticals, Inc.

Alan Crane

Robert Samuel Langer

Alexander M Klibanov

Kevin Thomas Love

Alyssa M Larson

Alisha K Weight

Donald E Chickering, Iii

Rakesh K Jain

Joanne Louise Viney

Lawrence Alan Reiter

Nathan Higginson-Scott

Micah Benson

Robert S Langer, Jr

Dai Fukumura

Peter Blume-Jensen

Rong Tong

Robert S Langer

Paul W Kopesky

Vikash Pal Singh Chauhan

Joao Incio

Noah Lee Crane

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.

Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC)

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.

Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP)

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of polysaccharides and nucleic acids have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight polysaccharides and nucleic acids, and viscosity-lowering agents.

Polysaccharide and nucleic acid formulations containing viscosity-lowering agents

Provided herein are polymers, pH-sensitive polymers and/or linkers; conjugates comprising said polymers and/or linkers, optionally, coupled to one or more agents and/or targeting moieties; and particles (e.g., nanoparticles comprising the aforesaid polymers, linkers and/or conjugates), which can be used to enhance the delivery and/or efficacy of one or more agents in a subject.

Polyacetal polymers, conjugates, particles and uses thereof

Methods and compounds for conferring site-specific or local immune privilege.

Targeted immunotolerance

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.

Liquid Protein Formulations Containing Thiamine

Liquid protein formulations containing 4-(3-butyl-1-imidazolio)-1-butane sulfonate (BIM)

Liquid protein formulations containing thiamine pyrophosphate (TPP)

Liquid protein formulations containing cimetidine

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering water soluble organic dyes.

Liquid pharmaceutical formulations for injection comprising yellow 5 or orange G and uses thereof

The present invention is directed at coatings for oven bake clay that when applied make the surface of the resulting object food safe. Among the many different possibilities contemplated, the coating may contain one or more food safe plastics that may be in particle form and may form suspensions or colloids when mixed with water, food safe oil or other food safe liquids to ease application. Among the many potential additional ingredients contemplated, the coating may contain one or more surfactants to improve the formation of a suspension or colloid or one or more food safe dyes so that the oven bake clay can be painted. Among the many methods of making the coating contemplated, the components may be mixed to form a suspension or colloid through one or more of agitation, stirring or sonication. It is further contemplated that the coating may be applied to an unbaked oven bake clay object and then baked or alternatively applied to a baked oven bake clay object and then re-baked.

Glaze-like coatings used to make oven bake clays food and drink safe

Liquid pharmaceutical formulations for injection comprising procaine and uses thereof

Liquid pharmaceutical formulations for injection comprising thiamine pyrophosphate 1-(3-aminopropyl)-2-methyl-1H-imidazole and uses thereof

Liquid protein formulations for injection comprising 1-butyl-3-methylimidazolium methanesulfonate and uses thereof

Growing community of inventors

Waban, MA, United States of America

Alan Crane